Evidence map›Paper›PMID 39392552›Full record

ArticleCell biochemistry and biophysics2025

Study of TRAIL and SAHA Co-Treatment on Leukemia K562 Cell Line.

Amirarsalan Alaei, Saeed Solali, Masoud Mohammad Mirzapour

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amirarsalan AlaeiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID http://orcid.org/0009-0001-0129-9572
Saeed SolaliMolecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ssolali@gmail.com.ORCID http://orcid.org/0000-0002-6487-3551
Masoud Mohammad MirzapourImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID http://orcid.org/0000-0002-7154-4393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) is an attractive agent being considered a potential cancer treatment. It attaches to its death receptors, leading many cancer cells to apoptosis. However, some malignancies indicate substantial resistance to TRAIL, challenging anticancer scientists. Herein, combination therapy with TRAIL plus SAHA (Suberoyl Anilide Hydroxamic Acid) was conducted to evaluate the capability of SAHA to overcome TRAIL resistance in the leukemia K562 cell line. First, the IC

Indexed as

Antineoplastic AgentsHydroxamic AcidsTNF-Related Apoptosis-Inducing LigandApoptosisDrug Resistance, NeoplasmHEK293 CellsHumansK562 CellsNF-kappa BProto-Oncogene Proteins c-aktReceptors, TNF-Related Apoptosis-Inducing LigandSignal TransductionSTAT3 Transcription FactorTranscription Factor CHOPVorinostatAntineoplastic AgentsHydroxamic AcidsNF-kappa BProto-Oncogene Proteins c-aktReceptors, TNF-Related Apoptosis-Inducing LigandSTAT3 Transcription FactorTNF-Related Apoptosis-Inducing LigandTranscription Factor CHOPVorinostatApoptosisHematologic MalignancyK562ResistanceSAHATRAIL

Identifiers

PMID39392552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.